Sun Pharma to Acquire ProMIS Neurosciences for $117M
Ticker: PMN · Form: 8-K · Filed: Jul 7, 2025 · CIK: 1374339
| Field | Detail |
|---|---|
| Company | Promis Neurosciences Inc. (PMN) |
| Form Type | 8-K |
| Filed Date | Jul 7, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, pharma, deal
TL;DR
Sun Pharma buying ProMIS for $3.20/share cash, deal valued at $117M, expected Q3 close.
AI Summary
ProMIS Neurosciences Inc. announced on July 3, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Sun Pharmaceutical Industries Ltd. for $3.20 per share in cash. This transaction values ProMIS at approximately $117 million. The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Sun Pharma could accelerate the development of ProMIS's Alzheimer's disease therapies, potentially bringing new treatments to patients sooner.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and there's always a risk of regulatory hurdles or other unforeseen issues that could delay or prevent the deal from closing.
Key Numbers
- $117M — Acquisition Value (Total enterprise value of the deal)
- $3.20 — Per Share Price (Cash consideration for each ProMIS share)
Key Players & Entities
- ProMIS Neurosciences Inc. (company) — Company being acquired
- Sun Pharmaceutical Industries Ltd. (company) — Acquiring company
- $3.20 (dollar_amount) — Per share acquisition price
- $117 million (dollar_amount) — Total acquisition value
- July 3, 2025 (date) — Date of definitive agreement
- third quarter of 2025 (date) — Expected closing period
FAQ
What is the primary therapeutic focus of ProMIS Neurosciences?
ProMIS Neurosciences focuses on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease.
Who is acquiring ProMIS Neurosciences?
A subsidiary of Sun Pharmaceutical Industries Ltd. is acquiring ProMIS Neurosciences.
What is the total value of the acquisition?
The acquisition is valued at approximately $117 million.
What is the price per share being offered?
The offer price is $3.20 per share in cash.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 7, 2025 regarding ProMIS Neurosciences Inc. (PMN).